acute lymphoblastic leukaemia
NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia
The treatments are for eligible adults in England and Wales
NICE recommends Genmab’s Tivdak for recurrent or metastatic cervical cancer
It is estimated that 3,300 women are diagnosed with cervical cancer in the UK each year
Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD
Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed
Amgen agrees to lower prescription drug costs in deal with US government
The company has invested $40bn in US R&D and manufacturing in the past seven years
Amgen reports positive results from landmark cardiovascular study
The study found significant reductions of major cardiovascular events in high-risk adults following treatment
ViiV Healthcare receives NICE recommendation for HIV prevention therapy
The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales
Pfizer’s Lorviqua recommended by NICE for lung cancer
Lung cancer is the leading cause of cancer-related deaths worldwide
Amgen commits $650m to US manufacturing expansion
The investment is expected to generate up to 750 new jobs
Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis
The phase 3 study included around 2,600 patients
NICE recommends ALK’s immunotherapy to target underlying cause of hay fever
An estimated 26,800 people in England with moderate-to-severe cases could benefit from Itulazax
NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS
Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK
Novartis’ Kisqali recommended by NICE to treat broad early breast cancer population
The drug was previously available only for patients whose cancer had spread to nearby lymph nodes